Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and ...

Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111)

Related Keywords

United States ,Boston ,Massachusetts ,Marcio Souza ,Exchange Commission ,Nasdaq ,Twitter ,Praxis Precision Medicines Inc ,Facebook ,Media Contact Ian Stone Canale Communications ,Linkedin ,Daily Living ,Praxis Precision Medicines ,Essential Tremor ,Precision Medicines ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Although Praxi ,Contact Praxis Precision Medicines ,Contact Ian Stone Canale Communications ,Region ,